ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
+50.81%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$224M
AUM Growth
+$224M
(+54%)
Cap. Flow
+$50M
Cap. Flow
% of AUM
22.34%
Top 10 Holdings %
Top 10 Hldgs %
52.9%
Holding
93
New
25
Increased
11
Reduced
6
Closed
20
Top Buys
| 1 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$9.34M |
| 2 |
Biohaven
BHVN
|
$7.66M |
| 3 |
Viking Therapeutics
VKTX
|
$6.97M |
| 4 |
CYBN
Cybin
CYBN
|
$5.77M |
| 5 |
Larimar Therapeutics
LRMR
|
$5.28M |
Top Sells
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$9.75M |
| 2 |
Astria Therapeutics
ATXS
|
$8.27M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$3.73M |
| 4 |
Immunovant
IMVT
|
$3.37M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
$2.62M |
Sector Composition
| 1 | Healthcare | 96.93% |
| 2 | Consumer Discretionary | 1.54% |
| 3 | Industrials | 0.07% |
| 4 | Communication Services | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vera Therapeutics
VERA
$1.38B
| $30.6M | 12.12% | 710,000 +95,000 | +15% | +$4.1M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $15M | 5.93% | 348,000 +57,465 | +20% | +$2.47M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $11M | 4.36% | 138,000 | – | – |
|
4
ADMA Biologics
ADMA
$4.12B
| $10.2M | 4.02% | 1,540,000 +445,000 | +41% | +$2.94M |
|
|
ALIM
5
DELISTED
Alimera Sciences, Inc.
ALIM
| $9.95M | 3.94% | 2,550,000 -110,000 | -4% | -$429K |
|
|
AVDL
6
Avadel Pharmaceuticals
AVDL
$1.43B
| $9.34M | 3.7% | +553,057 | New | +$9.34M |
|
7
Xtant Medical Holdings
XTNT
$83.3M
| $8.95M | 3.54% | 7,647,873 -379,720 | -5% | -$444K |
|
8
Catalyst Pharmaceutical
CPRX
$2.52B
| $7.97M | 3.15% | 500,000 +115,000 | +30% | +$1.83M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.82M | 3.09% | 113,000 +42,000 | +59% | +$2.91M |
|
|
10
Biohaven
BHVN
$1.63B
| $7.66M | 3.03% | +140,000 | New | +$7.66M |
|
|
11
Viking Therapeutics
VKTX
$3.04B
| $6.97M | 2.76% | +85,000 | New | +$6.97M |
|
12
Olema Pharmaceuticals
OLMA
$375M
| $6.85M | 2.71% | 605,000 +191,393 | +46% | +$2.17M |
|
13
Savara
SVRA
$567M
| $6.65M | 2.63% | 1,335,000 +2,000 | +0.2% | +$9.96K |
|
14
Soleno Therapeutics
SLNO
$3.6B
| $6.54M | 2.59% | 152,909 +48,000 | +46% | +$2.05M |
|
|
CYBN
15
Cybin
CYBN
$176M
| $5.77M | 2.28% | +13,953,488 | New | +$5.77M |
|
|
16
Oric Pharmaceuticals
ORIC
$994M
| $5.57M | 2.2% | 405,000 -271,000 | -40% | -$3.73M |
|
|
17
Larimar Therapeutics
LRMR
$310M
| $5.28M | 2.09% | +695,000 | New | +$5.28M |
|
18
Mirum Pharmaceuticals
MIRM
$3.71B
| $5.22M | 2.07% | +208,000 | New | +$5.22M |
|
19
Neurogene
NGNE
$264M
| $5.09M | 2.01% | 100,000 +33,019 | +49% | +$1.68M |
|
20
Praxis Precision Medicines
PRAX
$958M
| $4.77M | 1.89% | +78,100 | New | +$4.77M |
|
21
Achieve Life Sciences
ACHV
$152M
| $3.8M | 1.5% | +835,470 | New | +$3.8M |
|
22
Ascendis Pharma
ASND
$11.8B
| $3.78M | 1.5% | 25,000 | – | – |
|
|
LBPH
23
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $3.67M | 1.45% | +170,000 | New | +$3.67M |
|
24
Insmed
INSM
$28.8B
| $3.26M | 1.29% | 120,000 | – | – |
|
25
The RealReal
REAL
$879M
| $3.13M | 1.24% | +800,000 | New | +$3.13M |
|